Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Cancer Research|April 17, 2004
Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analoguesS Sianna Castillo, John Brognard, Pavel A Petukhov, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
Plos One|September 3, 2011
Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistanceChunyu Zhang, Abdel G Elkahloun, Matthew Robertson, et al.
The Oncologist|July 28, 2019
A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTENTakefumi Komiya, Gideon M Blumenthal, Roopa DeChowdhury, et al.
Clinical Lung Cancer|July 23, 2021
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)Mark A Socinski, Mustafa Özgüroğlu, Augusto Villegas, et al.
Plos One|March 31, 2009
A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesisCourtney A Granville, Regan M Memmott, Andria Balogh, et al.
Cancer Research|December 6, 2015
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung CancerKristin J Lastwika, Willie Wilson, Qing Kay Li, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 13, 2005
The biology of tobacco and nicotine: bench to bedsidePhillip A Dennis, Carter Van Waes, J Silvio Gutkind, et al.
Clinical Lung Cancer|July 23, 2019
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer PatientsSriram Sridhar, Luis Paz-Ares, Hao Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 7, 2020
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)Corinne Faivre-Finn, David R Spigel, Suresh Senan, et al.
Pageof 9